Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue

Five patients with metastatic pancreatic endocrine tumours injected a long acting somatostatin analogue (SMS 201-995) 50 micrograms subcutaneously every 12 hours and were followed up for three to six months. Treatment aimed at controlling excess secretion of hormone by the tumours thereby bringing s...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1986-04, Vol.292 (6526), p.981-982
Main Authors: Ch'ng, J L, Anderson, J V, Williams, S J, Carr, D H, Bloom, S R
Format: Article
Language:English
Subjects:
Acting
Adult
Aged
Blood glucose
Blood Glucose - metabolism
Clinical Research
Diarrhea
Disease remission
Exanthema
Fasting
Female
Glucagon - blood
Growth Hormone-Releasing Hormone - blood
Hormones
Humans
Male
Middle Aged
Neoplasia
Neoplasm Metastasis
Octreotide
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - drug therapy
Receptors, Opioid
Secretion
Somatostatin - analogs & derivatives
Somatostatin - therapeutic use
Vasoactive Intestinal Peptide - blood
Vipoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Five patients with metastatic pancreatic endocrine tumours injected a long acting somatostatin analogue (SMS 201-995) 50 micrograms subcutaneously every 12 hours and were followed up for three to six months. Treatment aimed at controlling excess secretion of hormone by the tumours thereby bringing symptomatic relief. Four patients showed a significant reduction in tumour related hormone concentrations but in none did values return to normal. All five patients, however, noted definite symptomatic improvement and in one this was dramatic (disappearance of life threatening diarrhoea and correction of metabolic acidosis and hypokalaemia within 48 hours). Mild worsening of symptoms and increasing fasting tumour related hormone concentrations after three to six months of treatment were reversed by doubling the 12 hourly dose. The treatment was well tolerated and had no deleterious effect on fasting blood glucose concentrations. This somatostatin analogue seems a promising non-invasive treatment for metastatic pancreatic endocrine tumours.
ISSN:0267-0623
0959-8138
1468-5833
DOI:10.1136/bmj.292.6526.981